Camp4 Therapeutics (CAMP) Equity Average (2023 - 2026)

Camp4 Therapeutics' Equity Average history spans 3 years, with the latest figure at $53.2 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 211.0% to $53.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.2 million, a 211.0% increase, with the full-year FY2025 number at $55.4 million, up 282.96% from a year prior.
  • Equity Average hit $53.2 million in Q4 2025 for Camp4 Therapeutics, up from $49.3 million in the prior quarter.
  • Over the last five years, Equity Average for CAMP hit a ceiling of $57.4 million in Q1 2025 and a floor of -$153.0 million in Q3 2024.
  • Historically, Equity Average has averaged -$42.6 million across 3 years, with a median of -$47.9 million in 2024.
  • Biggest five-year swings in Equity Average: soared 59.27% in 2024 and later surged 211.0% in 2025.
  • Tracing CAMP's Equity Average over 3 years: stood at -$117.6 million in 2023, then soared by 59.27% to -$47.9 million in 2024, then surged by 211.0% to $53.2 million in 2025.
  • Business Quant data shows Equity Average for CAMP at $53.2 million in Q4 2025, $49.3 million in Q3 2025, and $45.8 million in Q2 2025.